Trial Profile

A phase I clinical trial of Programmed cell death protein 1 gamma-delta chimeric antigen receptor T cell therapy (Procel™), in combination with a standard anticancer therapy, for the treatment of solid tumours

Status: Planning

Phase of Trial: Phase I

Latest Information Update: 29 Jun 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Programmed cell death protein 1 gamma-delta chimeric antigen receptor T cell therapy-Kiromic (Primary) ; Antineoplastics
Indications Solid tumours
Focus Adverse reactions
Sponsors Kiromic

29 Jun 2022 New trial record
21 Jun 2022 According to a Kiromic Biopharma media release, the company plans to file an IND for Procel™ in combination with standard antitumor modality in 2023 with clinical activation expected in Q2 2023.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com